Myriad Genetics presents data on cancer recurrence detection test

Myriad Genetics (MYGN) reported data showing its WGS-based Precise MRD detected ctDNA post-surgery in colorectal cancer with a 4-month lead over clinical recurrence and initial utility in pancreatic cancer. The company aims to expand into whole-genome MRD with emerging clinical evidence.

Myriad Genetics (MYGN) reported data from the MONSTAR-SCREEN-3 study, showing its Precise MRD™ platform detected cancer DNA before recurrence in colorectal and pancreatic cancer patients, with a median lead time of four months. The findings will be presented at the ESMO Congress 2026.

Myriad Genetics (MYGN) surged 40% after agreeing to sell its Prenatal Health business to Labcorp for $210M. Moleculin Biotech (MBRX) rose 15% on AML trial progress. Femasys (FEMY) and Revolution Medicines (RVMD) each gained 7% on commercial and clinical developments.

Myriad Genetics (MYGN) shares rose 36.94% to $5.77 on news of selling its Prenatal Health testing business to Labcorp (LH) for $210M in cash. The deal, expected to close in early 2027, is projected to boost MYGN's revenue growth and profitability, according to the company. Labcorp anticipates $160M in revenue from the acquisition in its first year.

EQT offered $50+ per share for Qiagen, raising its stock 5.8%. Labcorp agreed to buy Myriad Genetics' prenatal testing unit for $210M, boosting Myriad 36% and Labcorp 1%. GeneDx gained on sequencing plans. Investors focus on deal probabilities and sector-wide M&A expectations.

TD Cowen reiterated a Hold rating and $4.50 price target on Myriad Genetics (MYGN) after it agreed to sell its Prenatal Health business to Labcorp for $210M. MYGN shares trade at $5.76, with a market cap of $550M. The sale aims to simplify the company's portfolio and focus on Cancer Care Continuum. MYGN reported Q2 2026 revenue of $190.7M, down 11% YoY, missing estimates. Piper Sandler downgraded MYGN to Underweight with a $2 price target.